| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the BioMag Laboratory, Medical Engineering Center (Dr. Lauronen), Departments of Radiology (Drs. Lauronen, Autti, and Häkkinen) and Pediatric Neurology, Hospital for Children and Adolescents (Drs. Puranen, Kirveskari, and Santavuori), Helsinki University Central Hospital, Finland; the Laboratory of Human Molecular Genetics (Dr. Järvelä), National Public Health Institute, Helsinki, Finland; and the Department of Pediatrics (Drs. Munroe, Mitchison, O’Rawe, Gardiner, and Mole), University College London Medical School, The Rayne Institute, London, England.
Address correspondence and reprint requests to Dr. Leena Lauronen, BioMag Laboratory, PO Box 508, Fin-00029, HYKS, Finland.
OBJECTIVE: To correlate the phenotypes with the genotypes of 10 Finnish juvenile neuronal ceroid lipofuscinosis (JNCL; late-onset Batten disease) patients who all are compound heterozygotes for the major 1.02-kb deletion in the CLN3 gene.
METHODS: The mutations on the non–1.02-kb deletion chromosomes were screened in 6 patients; in the other 4 patients the mutations were known (one affecting a splice site, two missense mutations, and one deletion of exons 10 through 13). Clinical features were examined, and MRI, MRS, somatosensory evoked magnetic field (SEF), and overnight polysomnography (PSG) studies were performed.
RESULTS: A novel deletion of exons 10 through 13 was found in 6 patients belonging to three families. In the patients carrying the deletions of exons 10 through 13 the clinical course of the disease was fairly similar. Variation was greatest in the time course to blindness. In these patients the mental and motor decline was slower than in classic JNCL, but more severe than in the two patients with missense mutations in exons 11 and 13. MRI showed brain atrophy in 4 patients. One patient had hyperintense periventricular white matter, otherwise brain signal intensities were normal. SEFs were enhanced in patients older than 14 years, whereas in PSG all but the youngest 6-year-old patient showed epileptiform activity in slow-wave sleep.
CONCLUSIONS: JNCL can manifest as at least three different phenotypes: classic, delayed classic, and protracted JNCL with predominantly ocular symptoms. Finnish compound heterozygotes have the delayed classic or the protracted form of JNCL.
This article has been cited by other articles:
|
|
 |
|
  R. L. Haines, S. Codlin, and S. E. Mole The fission yeast model for the lysosomal storage disorder Batten disease predicts disease severity caused by mutations in CLN3 Dis. Model. Mech., January 1, 2009; 2(1-2): 84 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Gachet, S. Codlin, J. S. Hyams, and S. E. Mole btn1, the Schizosaccharomyces pombe homologue of the human Batten disease gene CLN3, regulates vacuole homeostasis J. Cell Sci., December 1, 2005; 118(23): 5525 - 5536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Marshall, E. A. de Blieck, J. W. Mink, L. Dure, H. Adams, S. Messing, P. G. Rothberg, E. Levy, T. McDonough, J. DeYoung, et al. A clinical rating scale for Batten disease: Reliable and relevant for clinical trials Neurology, July 26, 2005; 65(2): 275 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tyynela, T. Autti, M. Haltia, and S. E. Mole Pirkko Santavuori (1933-2004) J Child Neurol, June 1, 2004; 19(6): 465 - 470. [PDF]
|
|
|
|
|
|
K. E. Wisniewski, N. Zhong, and M. Philippart Pheno/genotypic correlations of neuronal ceroid lipofuscinoses Neurology, August 28, 2001; 57(4): 576 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Johnson, G. P. Cofer, S. L. Gewalt, and L. W. Hedlund Morphologic Phenotyping with MR Microscopy: The Visible Mouse Radiology, March 1, 2002; 222(3): 789 - 793. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
